1. Porfidia, A, Valeriani, E, Pola, R, et al. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res 20202020; 196: 67–74.
Google Scholar | Crossref | Medline2. Bowles, L, Platton, S, Yartey, N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. New Engl J Med 2020; 383: 288–290.
Google Scholar | Crossref | Medline3. Wichmann, D, Sperhake, JP, Lütgehetmann, M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020; 173: 268–277.
Google Scholar | Crossref | Medline4. Klok, FA, Kruip, MJHA, van der Meer, NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020; 191: 148–150.
Google Scholar | Crossref | Medline5. Middeldorp, S, Coppens, M, Haaps, TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost 2020; 18: 1995–2002.
Google Scholar | Crossref | Medline6. Kubes, P, Suzuki, M, Granger, DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 1991; 88: 4651–4655.
Google Scholar | Crossref | Medline | ISI7. Chaturvedi, S, Brodsky, RA, McCrae, KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol 2019; 10: 449.
Google Scholar | Crossref | Medline8. Cugno, M, Meroni, PL, Gualtierotti, R, et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun 2021; 116: 102560.
Google Scholar | Crossref | Medline9. Leppkes, M, Knopf, J, Naschberger, E, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 2020; 58: 102925.
Google Scholar | Crossref | Medline10. Meng, H, Yalavarthi, S, Kanthi, Y, et al. In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis. Arthritis Rheumatol 2017; 69: 655–667.In
Google Scholar | Crossref | Medline11. Varga, Z, Flammer, AJ, Steiger, P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418.
Google Scholar | Crossref | Medline12. Ruiz-Ortega, M, Lorenzo, O, Rupérez, M, et al. Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol 2001; 135: 123–137.
Google Scholar | Crossref13. Ahmetaj-Shala, B, Peacock, TP, Baillon, L, et al. Resistance of endothelial cells to SARS-CoV-2 infection in vitro. BioRxiv Immunology 2020. DOI: 10.1101/2020.11.08.372581.
Google Scholar | Crossref14. Corban, MT, Duarte-Garcia, A, McBane, RD, et al. Antiphospholipid syndrome. J Am Coll Cardiol 2017; 69: 2317–2330.
Google Scholar | Crossref | Medline15. Giardini, V, Carrer, A, Casati, M, et al. Increased sFLT‐1/PlGF ratio in COVID ‐19: a novel link to angiotensin II ‐mediated endothelial dysfunction. Am J Hematol 2020; 95. DOI: 10.1002/ajh.25882.
Google Scholar | Crossref | Medline16. Mortensen, SA, Sander, B, Jensen, RK, et al. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. Proc Natl Acad Sci 2017; 114: 986–991.
Google Scholar | Crossref | Medline17. Yu, J, Yuan, X, Chen, H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020; 136: 2080–2089.
Google Scholar | Crossref | Medline18. Magro, C, Mulvey, JJ, Berlin, D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220: 1–13.
Google Scholar | Crossref | Medline19. Rand, JH, Wu, XX, Wolgast, LR, et al. A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. Thromb Res 2017; 156: 119–125.
Google Scholar | Crossref | Medline20. Chaturvedi, S, Braunstein, EM, Yuan, X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135: 239–251.
Google Scholar | Crossref | Medline21. Valenti, L, Griffini, S, Lamorte, G, et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. J Autoimmun 2021; 117: 102595.
Google Scholar | Crossref | Medline22. Tang, N, Bai, H, Chen, X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094–1099.
Google Scholar | Crossref | Medline23. Zuo, Y, Yalavarthi, S, Shi, H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight 2020;5(11):e138999. DOI: 10.1172/jci.insight.138999.
Google Scholar | Crossref | Medline24. Skendros, P, Mitsios, A, Chrysanthopoulou, A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 2020; 130: 6151–6157.
Google Scholar | Crossref | Medline25. Sule, G, Kelley, WJ, Gockman, K, et al. Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by β2 integrin Mac‐1. Arthritis Rheumatol 2020; 72: 114–124.
Google Scholar | Crossref | Medline26. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
Google Scholar | Crossref | Medline27. Luo, XH, Zhu, Y, Mao, J, et al. T cell immunobiology and cytokine storm of COVID‐19. Scand J Immunol 2021; 93. DOI: 10.1111/sji.12989.
Google Scholar | Crossref | Medline28. Stouthard, JML, Levi, M, Hack, CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738–742.
Google Scholar | Crossref | Medline29. Devreese, KMJ, Linskens, EA, Benoit, D, et al. Antiphospholipid antibodies in patients with COVID‐19: A relevant observation? J Thromb Haemost 2020; 18: 2191–2201.
Google Scholar | Crossref | Medline30. Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
Google Scholar | Crossref | Medline | ISI31. Zhang, Y, Cao, W, Jiang, W, et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis 2020; 50: 580–586.
Google Scholar | Crossref | Medline32. Devreese, KMJ, Groot, PG, Laat, B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis. J Thromb Haemost 2020; 18: 2828–2839.
Google Scholar | Crossref | Medline33. Borghi, MO, Beltagy, A, Garrafa, E, et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol 2020; 11: 584241.
Google Scholar | Crossref | Medline34. Tripodi, A, Chantarangkul, V, Clerici, M, et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115: 672–678.
Google Scholar | Crossref | Medline | ISI35. Xiao, M, Zhang, Y, Zhang, S, et al. Antiphospholipid antibodies in critically Ill patients with COVID‐19. Arthritis Rheumatol 2020; 72: 1998–2004.
Google Scholar | Crossref | Medline36. Gatto, M, Perricone, C, Tonello, M, et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol 2020; 38: 754–759.
Google Scholar | Medline37. Zuo, Y, Estes, SK, Ali, RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Trans Med 2020; 12: eabd3876.
Google Scholar | Crossref | Medline38. Wenzel, C, Stoiser, B, Locker, GJ, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 2002; 30: 763–770.
Google Scholar | Crossref | Medline | ISI39. Shi, H, Zuo, Y, Navaz, S, et al. Endothelial cell-activating antibodies in COVID-19. MedRxiv: 2021: 21250041. DOI: 10.1101/2021.01.18.21250041.
Google Scholar | Crossref40. Hasan Ali, O, Bomze, D, Risch, L, et al. Erratum to: severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) A and antiphospholipid IgA antibodies. Clin Infect Dis 2020; 73(9):1746.
Google Scholar | Crossref41. Spyropoulos, AC, Levy, JH, Ageno, W, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost 2020; 18: 1859–1865.
Google Scholar | Crossref | Medline42. Zambrano, LD, Ellington, S, Strid, P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1641–1647. DOI: 10.15585/mmwr.mm6944e3.
Google Scholar | Crossref | Medline43. Greinacher, A, Thiele, T, Warkentin, TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. New Engl J Med 2021; 384: 2092–2101.
Google Scholar | Crossref | Medline44. Loarce-Martos, J, García-Fernández, A, López-Gutiérrez, F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 2020; 40: 2015–2021.
Google Scholar | Crossref | Medline45. Boyarsky, BJ, Ruddy, JA, Connolly, CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80: 1098–1099.
Google Scholar | Crossref46. Strakhan, M, Hurtado-Sbordoni, M, Galeas, N, et al. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol 20142014; 2014: 1–7.
Google Scholar47. Mastellos, DC, Pires da Silva, BGP, Fonseca, BAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol 2020; 220: 108598.
Google Scholar | Crossref | Medline48. Vargas, A, Boivin, R, Cano, P, et al. Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma. Respir Res 2017; 18: 207.
Google Scholar | Crossref | Medline49. Ali, RA, Gandhi, AA, Meng, H, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nat Commun 2019; 10: 1916.
Google Scholar | Crossref |